Denmark-based, Tetra Pharm Technologies (TPT) is a biotech startup committed to treat neuropathic pain & mental health disorders, by “designing & developing new drug formulations/ candidates, conducting clinicals & commercializing medicines targeting the endocannabinoid system (ECS)”. <Quick primer on the ECS: it regulates & controls many critical body functions such as, via CB1 receptors (found mostly in the brain) - learning & memory, emotional processing, sleep, temperature control, pain control, & via CB2 receptors (found mostly in tissue) - inflammatory & immune responses >. Worth keeping mind, the European market for cannabinoid-based treatment is expected to reach €3.2b by 2025. TPT is said to have closed “several significant distribution deals” across main European markets &...

Pharmaceutical giant Bayer has agreed to acquire (terms not disclosed) UK-based Blackford Analysis - a "strategic imaging AI provider to radiology labs" (the company previously helped Bayer develop its Calantic Digital Solutions, as part of the G4A Digital Health Partnerships Program). Founded in 2009 by Ben Panter (CEO), Blackford Analysis assists radiology clinics & developers of clinical radiology products to build bespoke AI imaging tools. Through the company's "AI imaging marketplace", said can access third-party products to e.g. accelerate medical image aggregation & annotate relevant literature with scientific knowledge. Its worth noting that Bayer is shifting its radiology strategy from a focus on individual products (contrast dyes & injection systems) to becoming a “solutions provider”....